Pharmaceutical Online: Catalyst Earns a Spot on List of Top 10 Articles of 2017

A Catalyst-penned article on Trump’s deregulatory agenda has earned a [...]

Pharmaceutical Online: Catalyst Earns a Spot on List of Top 10 Articles of 2017 2018-01-29T19:44:04+00:00

Commissioner Gottlieb, CAR T-Cells, & The Future Of Rare Disease Therapies

Pharmaceutical Online- What do Commissioner Gottlieb’s recent statements on orphan [...]

Commissioner Gottlieb, CAR T-Cells, & The Future Of Rare Disease Therapies 2018-05-24T20:21:29+00:00

Innovation and FDA’s Regulatory Frameworks: Catalyst Co-Authors Explore How the Coming Data Shift Will Impact Medical Product Regulation in Therapeutic Innovation & Regulatory Science Article

Given rapid advances in technology and our understanding of disease, [...]

Innovation and FDA’s Regulatory Frameworks: Catalyst Co-Authors Explore How the Coming Data Shift Will Impact Medical Product Regulation in Therapeutic Innovation & Regulatory Science Article 2017-11-25T20:28:38+00:00

Former FDA Associate Commissioner Jill Hartzler Warner Joins Catalyst Team, Expanding the Firm’s Expertise in Regenerative Medicine, Rare Disease Drug Development and Combination Product Regulation

Press release Washington, DC – Catalyst Healthcare Consulting is pleased [...]

Former FDA Associate Commissioner Jill Hartzler Warner Joins Catalyst Team, Expanding the Firm’s Expertise in Regenerative Medicine, Rare Disease Drug Development and Combination Product Regulation 2017-11-25T20:28:58+00:00

Trump’s Deregulatory Agenda: What It Could Mean For Biopharma & Medtech Companies

Pharmaceutical Online- What do President Trump’s deregulatory executive orders mean [...]

Trump’s Deregulatory Agenda: What It Could Mean For Biopharma & Medtech Companies 2018-05-24T20:23:48+00:00